Introduction
Pulmonary Hypertension (PH) is a progressive degenerative disease that affects the vasculature in the lungs and heart. There are several classes of PH: Group 1 pulmonary arterial hypertension (PAH), group 2 PH secondary to left heart disease, group 3 PH secondary to lung disease, group 4 PH associated with chronic thrombo-embolism, and group 5 PH that is associated with several diseases such as renal failure and thyroid disease 1 . PAH is unique from the other classes because it is not a comorbidity, or in other words, it is not a secondary cause and was initially classified as primary PH 2 . PAH is characterized by constriction of the vasculature in the lungs that causes an increase in pressure in the pulmonary artery which is responsible for the movement of blood from the heart to the lungs. This buildup of pressure causes immense strain on the heart, and ultimately leads to right ventricular heart failure 3 . Untreated, the prognosis for patients with PAH is a few years, giving this disease a high morbidity and mortality. While there are several treatments available that can help to alleviate some of the symptoms of PAH, there is no means of reversing or curing the chronic rare disease. Recent studies have improved the genetic understanding of the disease, and these insights could lead to better therapeutic interventions. This is particularly true in the cases of idiopathic PAH and heritable PAH where there is no known outlying cause of the disease. This strongly suggests that there must be a genetic factor that is causing patients to develop PAH 4 . Studies have shown that mutations to the bone morphogenetic protein receptor type 2 (BMPR2) gene are found in a large percentage of patients that have heritable PAH, but these mutations are also found in cases where there is no familial history of the disease, making the link between BMPR2 and PAH unclear 5 . Another gene that has been recently identified in the progression of PAH is caveolin-1 6 . The knockout of caveolin-1 leads to several disease-like phenotypes due to the loss of caveolae on the cell surface. In particular, the absence of caveolin-1 leads to vascular deformities and PAH-like symptoms [7] [8] [9] [10] . Furthermore, there is reduced expression of caveolin-1 in the endothelial cells of PAH patients. It has been shown that BMPR2 localizes to caveolae and interacts directly with caveolin-1, and the stabilization of this interaction by the protein elafin has been shown to increase BMPR2 function 11, 12 . Another interaction that is affected by the loss of caveolin-1 is that between endothelial nitric oxide synthase (eNOS) and caveolin-1, which has been shown to have detrimental effects on endothelial health 13 .
Recently, mutations to the caveolin-1 C-terminal domain have been found in PAH patients 6 . In this mini-review we present research into the emerging relationship between caveolin-1 and PAH, and how mutations to the caveolin-1 C-terminal domain affect caveolin-1 function, particularly the effects on the caveolin-1/eNOS interaction ( Figure 1 ).
Caveolin-1
Caveolin-1 is a 178 amino acid integral membrane protein that is the primary protein component of 50-100 nm plasma membrane invaginations called caveolae. Caveolin-1 is often represented by four distinct structural domains: a soluble N-terminal domain, a scaffolding domain, a membrane domain, and a C-terminal domain [14] [15] [16] [17] . Recently, secondary structure assignments have shown that the C-terminal domain forms a long single alphahelix from residues 132-175 15 . The helix is amphipathic, and is thought to rest on the surface of the membrane 14, 15 . This interfacial interaction with the cell membrane is proposed to be enhanced by three cysteine residues, located in the C-terminal domain, that have been shown to be palmitoylated in vivo. However, the specific role(s) that palmitoylation play(s) in caveolin-1 function is currently unresolved, although it is clear that palmitoylation is not necessary for the proper trafficking of caveolin-1 to caveolae 18 . The C-terminal domain has also been cited as a key domain for the formation of the higher order oligomer/ oligomer interactions that are thought to be critical for stabilizing the highly curved shape of caveolae 19 . In addition, the C-terminal domain is important for caveolin-1's interaction with a number of important cellular proteins including connexin and Retrovirus NSP4 20, 21 . Recent in vivo studies in cells overexpressing caveolin-1 showed that the fate of the wild-type protein was highly dependent on the tag that was appended to the C-terminus 22 . This indicates that an unadulterated C-terminal domain may be vital for the proper function of caveolin-1, although more work is needed to completely justify this conclusion. Despite these clear indications that the C-terminal domain is important for caveolin-1 function, little is known about how variations in the C-terminal domain affect caveolin-1 structure and hence cellular behavior.
Caveolin-1 mutations associated with PAH
A recent study of patients with heritable and idiopathic PAH identified a novel frameshift mutation in the caveolin-1 protein, one that occurred in a family with heritable PAH, and the other in a child with idiopathic PAH. This frame shift occurs in the latter portion of the C-terminal domain of caveolin-1 at residue P158 which is identified as P158P fSX22 in the heritable form of the PAH, and P158H fx22 in the patient with idiopathic PAH 6 . Importantly, there was no evidence of either mutation in control subjects, indicating that the mutation was most likely related to PAH 23 . Patients experiencing this frameshift mutation showed a marked decrease in endothelial caveolin-1 in their lung tissue 6 . In addition, studies conducted on the fibroblasts of patients containing the P158P fSX22 mutation revealed that the mutated form of caveolin-1 can still form caveolae, but that the number of caveolae on the cell surface is significantly reduced 24 . It is interesting to note that both of these mutations occur after the three palmitoylation sites in the caveolin-1 C-terminal domain; therefore, it is unlikely that the reduction in the number of caveolae is due to alterations in caveolin-1 palmitoylation.
A deletion mutation, identified as F160X, has been found in a patient with PAH and congenital generalized lipodystrophy 25 . This truncated construct lacks the final 20 amino acids in the C-terminal domain, and is similar to the frameshift mutation in that it affects the latter half of the C-terminal domain. Han et al explored the effects of the F160X mutation on the formation and stability of caveolae. While it was found that the mutant protein was able to interact with wild-type caveolin-1, and form caveolae on its own, its oligomeric structure exhibited decreased stability 25 . In vivo, the C-terminal domain is resistant to immunostaining by C-terminal antibodies. However, when the F160X mutation is introduced, the C-terminal domain is exposed, and able to interact with these antibodies 25 . These studies show that behavior of the oligomeric complex formed by caveolin-1 is affected by the presence of the C-terminal truncation.
Studies have identified the C-terminal domain as being crucial for the formation of caveolin-1 oligomers 19 . The study by Han et al supports this by showing that the deletion of the C-terminal residues leads to the formation of less stable oligomers, but does not completely ablate oligomerization. In all of the mutations related to PAH, the last 20 amino acids are affected (either deleted or scrambled). The loss of these amino acids or disruptions, likely affects the amphipathic nature of the C-terminal helix. Consequently, this could affect not only homooligomeric interactions, but also lipid/protein interactions as the C-terminal domain has been shown to be important for membrane trafficking and attachment 26 . The loss of the amphipathic nature due to these mutations may account for a decrease in membrane trafficking, and account for lower levels of caveolin-1 found in PAH patients. This suggests that the amphipathic character of the C-terminal domain may be essential for proper caveolin-1 function.
Caveolin-1, eNOS synthase and PAH
Caveolae are highly abundant, and hence caveolin-1 is highly expressed in endothelial cells. Therefore, caveolin-1 is intimately related to endothelial health. Caveolin-1 null mice have been shown to be viable, but have severe cardiac and vascular defects. These defects are linked to the loss of caveolae on the cell surface 8 . In PH induced rat model systems, there is a decrease in caveolin-1 expression in endothelial cells, and the upregulation of several cellular pathways before the onset of PH 27 . In particular, the generation of nitric oxide (NO) by eNOS is affected by caveolin-1 depletion. eNOS is responsible for the production of NO in the vascular system that serves several roles such as the inhibition of platelet aggregation and adhesion 28 . Caveolin-1 has been shown to directly bind to eNOS, and this interaction inhibits the production of NO within endothelial cells 29 . Zhou et al studied the progression of PH in caveolin-1 and caveolin-1 and eNOS null mice. These studies revealed that in caveolin-1 null mice there was an increase in eNOS activity that led to PAH, while in the double knockout study (both caveolin-1 and eNOS null mice) there was no PH related vascular defects 30 . These studies show a direct link between the interaction of caveolin-1 with eNOS and the progression of PAH. It is important to note that there is a high similarity between human caveolin-1 and that of rat and mouse making the aforementioned studies particularly relevant to the human disease (95% and 96% similarity in rat and mouse respectively). In vitro studies monitoring the production of nitrite have shown that the scaffolding and C-terminal domains inhibit eNOS to the same extent as the wild-type protein 29 . This raises interesting questions about the location of these domains in the structure of caveolin-1. Are these domains spatially close such that they interact simultaneously, or do the two regions interact with eNOS independently? While there are several studies on the interaction of the caveolin-1 scaffolding domain and eNOS, there is a dearth of knowledge on how changes in the C-terminal domain affect caveolin-1/eNOS interactions 29, [31] [32] [33] . With the recent identification of C-terminal mutants within caveolin-1, it is now possible to explore how changes in the C-terminal domain affect eNOS behavior in terms of binding and inhibition of NO production. Studies of this type would also give insights into whether the loss of the eNOS interaction or lower levels of caveolae stability is most responsible for PAH progression.
Conclusion
Overall, the role of the caveolin-1 C-terminal domain has been undervalued when studying the cellular function of caveolin-1. With recent structural data, it is now possible to contextualize how mutations to the C-terminal structure may affect caveolin-1 and its interacting partners. Importantly, the caveolin-1 C-terminal domain mutations that are identified in patients with PAH show that this domain is critical for the stability of oligomers that are the bedrock of caveolae homeostasis. Interestingly, the C-terminal domain has also been shown to inhibit eNOS. This interaction is vital for proper vascular health, and disruption of this interaction via mutations in the C-terminal domain could clearly trigger a condition such as PAH. Further research into the role that the C-terminal domain plays in caveolin-1 biology, such as its role in other protein-protein interactions (i.e. BMPR2) will undoubtedly generate new insights into the underlying causal factors of PAH progression. This understanding is critical as there is currently no method for detecting the early stages of PAH within patients; often the disease has progressed to an irreparable extent when it is finally discovered. Promisingly, recent studies have shown that caveolin-1 can be used as a biomarker to help diagnose PAH early by assessing the levels of caveolin-1 expression in endothelial cells 34 . As more information becomes available on the relationship between caveolin-1 and PAH, it is likely that this new knowledge will facilitate the development of successful therapeutic interventions to mediate the effects of this debilitating disease.
